18F-fluciclovine and 68Ga-prostate specific membrane antigen (PSMA) are novel PET imaging radiotracers used to characterize disease burden in biochemical recurrent prostate cancer. 18F-fluciclovine was FDA-approved in 2016 and is reimbursed through public and private payers, while 68Ga-PSMA-11 is considered investigational and accessed through clinical trials.